IL32 and cancer: To further confirm the effector role of Src in PC‐IL32 mediated TKI sensitivity in cancer cells, we performed IC50 TKI experiments using EGFR‐mutated cancer cells treated with CM from PCs in the presence of TKI with or without Src inhibitor Dasatinib.